AI Investment Business Regulation

The ADA Just Put Its Money Where AI Is

Dr Ali Vatan Ali Vatan
·

The American Dental Association has made its first-ever investment in a dental AI company. What does it mean when the profession's governing body picks a side?

The ADA Just Put Its Money Where AI Is

On 17 December 2024, the American Dental Association made a strategic investment in Pearl, the LA-based company behind the first FDA-cleared AI for reading and identifying pathology in dental radiographs. The ADA hasn’t disclosed the exact sum, but the signal matters more than the cheque.

The ADA represents over 160,000 dentists in the United States. It shapes policy, influences regulation, and sets the tone for what the profession considers legitimate. When an institution like that puts money into an AI company, every dentist should notice.

Why Pearl, why now?

Pearl was founded in 2019 and has built its reputation on computer vision for dental imaging. Its AI has received regulatory clearance in over 120 countries and is designed to assist clinicians in making more precise diagnostic decisions from radiographs. The investment was led by the ADA’s Innovation Advisory Committee, which exists to identify technologies that could advance patient care and public health.

This isn’t technically the ADA’s first technology investment; they’ve previously invested in Oral Genome and Overjet. But the Pearl investment is significant because of timing. It arrives as dental AI attracts unprecedented venture capital (over $145 million in 2024 alone) and the profession grapples with what AI means for clinical practice.

The ADA doesn’t want to be left behind. I can understand why.

Institutional endorsement carries weight

When the ADA invests in Pearl, it’s not just a financial transaction. It’s an endorsement. And endorsements from professional bodies carry enormous weight with 160,000-plus member dentists who look to the ADA for guidance on everything from infection control to continuing education.

For practitioners who’ve been sceptical about AI, this sends a clear message: the governing body of American dentistry believes this technology has a place in clinical practice. For some dentists, it’s the nudge they needed. For others, it might feel like the profession is picking winners before the evidence is fully in.

I have some sympathy with both positions.

It’s very easy to be fooled by the magic of it

AI in dentistry is impressive. When you watch a system analyse a panoramic radiograph and highlight caries, bone loss, and periapical lesions in seconds, it genuinely looks like something new. It’s very easy to be fooled by the magic of it, by how a computer can seemingly think.

But thinking and proving are different things. We need long-term, real-world clinical data before we can say with confidence that AI-assisted diagnosis improves patient outcomes, not just diagnostic accuracy on curated datasets. There’s a gap between “this AI can identify a lesion on a radiograph” and “this AI makes patients healthier.”

We will have to wait and see what the real-world data shows.

The ADA’s investment is a vote of confidence, but it’s not a clinical trial. It’s not a systematic review. It’s a bet, an informed one made by people who understand the landscape, but a bet nonetheless.

What this means for UK dentistry

For those of us on this side of the Atlantic, the ADA’s move is worth watching. The British Dental Association hasn’t made equivalent investments and operates quite differently, but what happens in the US dental market tends to ripple outwards. If AI becomes standard of care in American practices, and the ADA’s endorsement accelerates that trajectory, it will eventually influence expectations here too.

The NHS raises its own questions about funding, training, data governance, and clinical responsibility that don’t have easy answers. But the direction of travel is clear.

The real test

Only time will tell how useful this is for the public. Pearl is a credible company with genuine regulatory credentials, and I respect the intent behind the ADA’s move. But we’re still early.

The real test isn’t whether AI can read an X-ray. It’s whether AI improves the care patients actually receive: catching things that would otherwise be missed, reducing diagnostic variability, making dentistry more equitable and more accessible.

References